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Abstract
Background
High quality diagnostic services are crucial for tuberculosis (TB) diagnosis, treatment and
control. A strong laboratory quality management system (QMS) is critical to ensuring the
quality of testing and results. Recent initiatives to improve TB laboratory quality have
focused on low and middle-income countries, but similar issues also apply to high-income
countries.
Methods and findings
Using a multipronged approach reviews of facilities, equipment, processes (purchasing,
pre-analytic, analytic and post-analytic), staff, health and safety, documentation, information
management and organization based on the ISO 15189 and the twelve quality system
essentials were conducted between October 2015 and January 2016 at the National TB
Reference Laboratory in Germany. Outcome assessment included proportion of smear pos-
itive slides, proportion of contaminated liquid cultures and DNA contamination rates before
and after implementation of QMS. The odds ratio for these outcomes was calculated using a
before/after comparison. Reviews highlighted deficiencies across all twelve quality system
essentials and were addressed in order of priority and urgency. Actions aimed at improving
analytical quality, health and safety and information management were prioritised for initial
implementation in parallel with each other. The odds ratio for a sample to be tested as micro-
scopically positive increased by 2.08 (95%CI 1.41–3.06) comparing the time before with the
time after implementation of quality managed fluorescence microscopy. Liquid culture con-
tamination rates decreased from 23.6- 7.6% in April-July 2016 to <10% in November 2017-
March 2018. The proportion of negative controls showing evidence of DNA contamination
decreased from 38.2% in 2013 to 8.1% in 2017, the corresponding odds ratio was 0.14
(95%CI 0.07–0.29).
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Conclusion
This study showed marked improvement on quality indicators after implementation of a
QMS in a National TB Reference Laboratory. The challenges and lessons learned in this
study are valuable not just for high-income settings, but are equally generalizable to other
laboratories.
Introduction
High-quality laboratory services are an essential component for tuberculosis care and control.
[1] New diagnostic methods and increasing awareness about medical errors and their conse-
quences emphasizes the great importance of quality in health.[2] A strong laboratory quality
management system (QMS) is critical to ensuring the quality of testing.
Over the last six decades laboratory quality management has experienced ongoing develop-
ment.[3] A ten-fold reduction in the analytical error rate has been achieved over the past
decade as a result of improved reliability and standardization of analytical techniques,
reagents, and instrumentation especially in clinical chemistry.[4–6] In addition, advances in
information technology, quality control and quality assurance methods have also led to error
reduction.
Laboratory quality management is generally accepted as state of the art practise and is
legally prescribed in many countries such as Germany and the USA.[7, 8] Integral parts of a
QMS, often implemented in the early stages of an improvement initiative, include quality con-
trol (QC), external quality assessment (EQA), standard operating procedures (SOP) and com-
petency assessment (CA). Several studies have shown that QMS implementation results in a
measurable improvement in the quality of services and increased patient safety due to a reduc-
tion in laboratory errors.[4, 9–11]
Germany is a low tuberculosis incident country with a total of 5915 tuberculosis patients
notified in 2016 amounting to an annual tuberculosis notification rate of 7.2 cases per 100 000
population.[12] Microbiological confirmation was obtained for 71.5% of all cases. The labora-
tory network in Germany comprises stand-alone microbiology laboratories run by district,
town or university hospitals, private laboratories and private laboratory companies operating
either regionally or nationally. Approximately 150 and 50 laboratories perform mycobacterial
culture and tuberculosis drug susceptibility testing (DST) respectively. Germany has an insur-
ance-based health care system with fixed prices for diagnostic tests. Different prices are applied
for in- and outpatients and for patient insured by standard or private insurance. Laboratories
are at liberty to offer discount packages. The National Mycobacterium Reference Laboratory
(NRL) was appointed by the Ministry of Health through consultation with the Robert Koch
Institute. The NRL receives some federal funding and generates revenue through diagnostic
procedures.
The NRL has been implementing a comprehensive and data-driven approach to improving
quality management systems at the laboratory, starting in 2015 with a detailed laboratory
review process. This review led to adoption of a phased implementation approach starting
with introduction of QM and health and safety policies, and building renovations. In 2017, a
laboratory information system (LIS) with audit trails, automated quality statistics and barcodes
was introduced. Here we present our experiences of implementing a QMS, challenges and les-
sons learned and the impact of the interventions based on measurement of trends in key qual-
ity indicators before, during and after implementation of various aspects of the QMS.
Quality management in diagnostics
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Methods
National Reference Laboratory
The NRL receives 12 000–15 000 samples every year. The samples are referred by the regional
referral hospital specializing in respiratory diseases (including tuberculosis and specifically
drug resistant tuberculosis) (30%), hospitals and private practitioners regionally (15%) and
other laboratories nationally (40%). The remaining 15% of samples are sent to the NRL in its
capacity as a WHO (World Health Organisation) supranational reference laboratory from
partner countries internationally. These samples are referred for DST as part of quality assur-
ance for national drug resistance surveys or for second line DST for rifampicin resistant iso-
lates from countries without local DST capacity. The NRL in partnership with INSTAND
(Gesellschaft zur Fo¨rderung der Qualita¨tssicherung in medizinischen Laboratorien e.V) runs
the twice-yearly mycobacterial EQAs for Germany and through a European Center for Disease
Prevention and Control (ECDC) funded scheme for countries in the European Union.
The NRL employs a director, two scientists, seven full-time and two part-time technicians,
two part-time laboratory assistants and two administrators.
Diagnostic procedures at the NRL include smear microscopy, solid and liquid mycobacte-
rial culture, direct molecular tests to detect non-tuberculosis mycobacterial (NTM) DNA,
Mycobacterium tuberculosis complex DNA and resistance conferring mutations, species identi-
fication, genotypic and phenotypic DST. The laboratory infrastructure includes biosafety level
II and III laboratories (BSL II and III).[13]
Laboratory review
A series of laboratory reviews was conducted between October 2015 and January 2016,
prompted by a change in laboratory leadership. Using a multipronged approach reviews of
facilities, equipment, processes (purchasing, pre-analytic, analytic and post-analytic), staff,
health and safety, documentation, information management and organization based on the
ISO 15189 and the twelve quality system essentials were conducted.[14]
The newly appointed clinical laboratory director together with an external quality manage-
ment consultant reviewed all available documents, directly observed sample processing and
analytic procedures, interviewed staff working in the laboratory and at core facilities (human
resources and central procurement). The results of the review were summarized in a narrative
report and a list of priorities areas for actions was drawn up. This was presented to the institu-
tional senior management resulting in additional resources for process optimization, infra-
structure, staff and laboratory information and data management.
In addition, the laboratory manager (previous quality manager) of the English National
Mycobacterial Reference Laboratory was invited for a 3-day visit to identify areas for improve-
ment mainly focused on analytic processes and health and safety of employees. Findings were
summarized in a supervisory report, presented both to senior management and laboratory
staff. The institutional health and safety officer, together with the head of technical services
and the clinical laboratory director undertook a detailed risk assessment aligned with the Ger-
man biosafety regulations.[15] In addition, a ventilation engineer was asked to review the ven-
tilation system and measure pressure differences and air exchanges.
Actions
Following the reviews, a quality manager and a quality management technician were
employed. One of the technicians was promoted to acting laboratory manager and funded to
undertake a two-year part-time course in laboratory management. As a result of the risk
Quality management in diagnostics
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assessment and the ventilation engineer report, a laboratory planner and architect was
commissioned to assess the feasibility of refurbishing existing facilities in order to comply with
the 2013-biosafety regulations.
Because the baseline reviews had identified deficiencies across all aspects of the twelve qual-
ity management essentials, the decision was taken to address deficiencies in order of priority
and urgency. Actions aimed at improving analytical quality, health and safety and information
management were prioritised for initial implementation in parallel with each other.
Outcomes
Impact was measured using quality indicators across three analytic methods before and after
implementing improvement activities: i) smear microscopy ii) liquid mycobacterial culture
and iii) molecular DST. Patient population, referring hospitals and sample numbers were com-
parable across different time periods. The prevalence of positive cultures for mycobacteria (M.
tuberculosis complex or non-tuberculous mycobacteria) was not significantly different before
and after the intervention (p = 0.10).
The proportion of smear positive slides from respiratory samples and the proportion of
false positive samples were calculated before, during and after implementing improvement
activities. Differences in proportions were compared using χ2 test. Odds ratios for smear posi-
tivity were calculated using the pre-implementation period as the baseline. Only the first respi-
ratory sample of a patient was included in the analysis. A false positive smear was defined as a
smear categorized as positive in treatment naïve patients without detection of mycobacterial
DNA in the primary sample, no mycobacterial growth in liquid media after 6 weeks and solid
culture after 8 weeks.
As part of the baseline review the proportions of contaminated liquid cultures were deter-
mined retrospectively over three consecutive months (February-May) and years (2013–2015)
by extracting data manually from paper records In line with routine laboratory procedures
positive liquid cultures were investigated using the standard Ziehl-Neelsen stain and light
microscopy, sub-culture on Columbia blood agar and Loewenstein-Jensen slants and molecu-
lar diagnostics aimed at detecting non-tuberculosis mycobacterial or M. tuberculosis complex
DNA. Our limited data collection allowed investigation into possible monthly and yearly vari-
ation while limiting the staff time required for the data extraction. Routine prospective collec-
tion of contamination rates as quality indicators was implemented in April 2016. According to
German microbiology standards contamination rates were calculated for sputum samples only
and restricted to treatment naïve patients, not known to have cystic fibrosis. [16] The propor-
tion of contaminated liquid cultures was determined over time.
For each Genotype MTBDRplus (HAIN Lifescience, Nehren, Germany) run performed
between 2013 and 2017 the number of samples tested and the result of the negative control
(positive or negative) were extracted from laboratory worksheets. The proportion of “positi-
ve”negative controls was calculated for each year and compared using χ2 test. Logistic regres-
sion was used to determine the odds ratios for PCR runs with evidence of DNA contamination
(“positive” negative control) with 2013 serving as the baseline comparison.
All statistical analysis was performed using Stata version 14.2 (Texas, USA).
Results
Baseline reviews, actions and results
Table 1 summarizes the findings of the baseline reviews and the resulting actions across the
twelve quality management essentials.
Quality management in diagnostics
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Table 1. Findings of the baseline reviews and the resulting action across twelve management essentials.
Quality system essential Review findings Actions Outcomes
(I)
Facilities and safety
Laboratory design,
geographic and spatial
organization
• Unrestricted access to BSL III
• No sample reception (sample
drop off in the hallway)
• Crossing circulation pathways
(biological samples,
contamination waste, staff)
• Lack of emergency exits
Lack of delineation of laboratory
activities
• Suboptimal separation of pre-
PCR, PCR and post-PCR
processes
▪ Access limited to authorized staff
▪ Planning and securing finances for a
new BSL III
▪ Optimising pathways within existing
infrastructure
▪ Building of three additional emergency
exits
▪ Clear delineation of laboratory
activities through process control and
infrastructural changes
▪ Separation of pre-PCR, PCR and post-
PCR processes by providing additional
bench space
Finance secured, BSL III design
underway, with planned completion
date Q3 2020
Decrease in DNA contamination from
38% to 8%
Physical aspects of
premises
• Inadequate physical
infrastructure and inappropriate
construction materials
▪ Planning and securing finances for a
new BSL III
Finance secured, BSL III design
underway, with planned completion
date Q3 2020
Safety management • Rudimentary laboratory safety
program
• No designated safety officer
• Limited standard safety
practises and inadequate staff
training
• Unsafe waste management
• Lack of autoclave validation and
servicing
• Ad hoc and unsupervised
cleaning of the BSL III by locum
cleaning staff
• Inadequate fire safety
equipment
• Lack of gas alarm
▪ Development of a laboratory safety
program
▪ Appointment of one of the technicians
to become health & safety officer
▪ Implementation of standard safety
practises in conjunction with extensive
health and safety training
▪ Development of a waste management
plan, procurement of appropriate
equipment (i.e. autoclave boxes,
transport vehicles) and consumables
(waste containers)
▪ Autoclave validation for solid and
liquid waste, establishment of a service
contract
▪ Development of a cleaning plan and
rota including laboratory staff only
▪ Upgrade of fire safety equipment
▪ Removal of bunsen burners and
decommissioning of gas supply
Laboratory safety program and waste
management plan established
Identification of risk • BSCs alterations potentially
influencing airflow
▪ Refurbishment of BSCs BSC refurbished
Personal protective
equipment
• No gloves policy ▪ Implementation of an “all gloves”
policy
▪ Training to staff
Emergency
management
• Lack of emergency management
plan
▪ Development of an emergency
management plan
(II)
Equipment
Troubleshooting,
service, repair and
retiring equipment
• Limited number of service
contracts
• Poor documentation of
maintenance and service
contracts
▪ Initiate service contracts
▪ Establish and maintain documentation
Equipment
maintenance
• No equipment inventory
• No equipment maintenance
program
• Limited BSC maintenance
▪ Compile equipment inventory
▪ Initiate an equipment maintenance
program
▪ 6 monthly BSC maintenance
Equipment inventory completed
(III)
Purchasing and
inventory
Purchasing • No purchasing process
• Documentation of purchasing
incomplete and variable
▪ Establish clear processes for selection,
purchasing and receipt of supplies
▪ Introduce forms and logs to document
purchasing and receipt of supplies
Inventory management • No inventory management
program
▪ Conduct an inventory serving as
baseline and implement regular stock
checks
Baseline inventory performed
Storage of supplies • Inadequate and non-
standardised storage procedures
▪ Improve storage of consumable (i.e.
regular temperatures checks)
(Continued)
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Table 1. (Continued)
Quality system essential Review findings Actions Outcomes
(IV-1)
Process control—
sample
management
Laboratory handbook • Available, but out-dated (i.e.
new diagnostic methods missing)
▪ Update laboratory handbook Updated laboratory handbook
Sample processing • Lack of sample rejection
criteria, leading to all samples
being processed regardless of
suitability
▪ Establish procedures to assess quality
of samples, introduce rules for rejecting
samples and standardise feedback to
referring clinicians
Sample rejection optimised
Sample storage,
retention and disposal
• Paper-based archiving system
without temperature control (at
-20C)
• Storage of >20,000 cultures for
up to 5 years in inadequate
secondary storage containers with
unrestricted access
▪ Computerised and temperature
controlled (-80) archiving of cultured
isolates in planning
▪ Deactivation of all cultures by
autoclaving and safe disposal
Deactivation of old cultures completed
(IV-2)
Process control—
quality control and
method validation
Quality control • Quality control of stains, solid
and liquid media (prepared in
house) and drug stock solutions
(prepared in house) not
performed
• Quality control of some
commercially sourced media and
drug stocks, but lack of
standardised documentation
▪ Implementation of lot control for
staining solutions, replacement of in
house media by commercially sourced
media
▪ Implementation of lot control
documentation for all media
Verifications completed for NTM DST,
fluorescence microscopy, Xpert1
MTB/RIF Ultra (Cepheid),
FluoroType1 MTBDR (HAIN
Lifescience), DST for new drugs
(bedaquiline, clofazimine, delamanid)
Method verification
and validation
• Verification and validation not
routinely performed
▪ Verification and validation of all newly
introduced methods
(V)
Assessment -audits
External and internal
audit
• External audits not performed
• Internal audits not performed
▪ Not yet performed
▪ Initiation of an internal audit program
starting with baseline reviews and some
selected horizontal audits (such as
temperature log keeping)
Baseline internal audit performed
Proficiency testing • Participation in the National
German EQA, run by the NRL
itself
• Participation in the WHO EQA
for first- and second-line DST for
TB
▪ Participation in the US CAP (college
of American pathology) EQA for
microscopy, NAT, culture, identification
and phenotypic DST
Successful participation of the first
round of CAP EQA
Certification and
accreditation
• Laboratory not accredited ▪ Accreditation to ISO 15189 standard
planned for 2020 (following the move
into the new BSL III)
(VI)
Personnel
Recruitment and
orientation
• No standardised process ▪ Development of SOPs for recruitment
and orientation
Competency and
competency assessment
• Competencies not recorded
• Competency assessment not
conducted
▪ Development of a competency matrix
and processes on how to assess
competence
Competency assessment reviewed and
approved by workers’ council
Training and
continuing education
• No regular in-house training
conducted
• Limited external training
opportunities for scientific staff
members only
▪ Initiation of fortnightly internal
training sessions covering pre-analytic
requirements, analytic processes,
documentation, information
management, data protection, health &
safety, fire safety
▪ Invitation of diagnostic companies to
provide on-site training of new and
established diagnostic methods
▪ Active encouragement and provision
of funding for visits to other laboratories
and external training for all staff
members including technicians and
administrators
27 internal group training sessions;
Completion of three one to one
training sessions for each staff member
before implementation of the new LIS;
48 external training days;
25 visits to other laboratories;
Completion of bachelor in laboratory
management (acting laboratory
manager);
Completion of bachelor economic
engineering (quality management
technician);
Completion of TB expert course
(ECDC) (biomedical scientist)
Employee performance
appraisal
• Not performed ▪ Regular (yearly) employee appraisals
by the clinical director
All staff have had two rounds of
appraisals
(Continued)
Quality management in diagnostics
PLOS ONE | https://doi.org/10.1371/journal.pone.0222925 October 15, 2019 6 / 17
Table 1. (Continued)
Quality system essential Review findings Actions Outcomes
(VII)
Customer Service
Assessing and
monitoring customer
satisfaction
• No document of customers’
complaints or compliments
• No processes for handling
complaints
▪ Documentation of customers’
complaints and compliments
(VIII)
Occurrence
management
Investigation of
occurrences
• No process for investigating
occurrences
▪ Implementation of a structured
document to investigate occurrence
▪ Regular review of all occurrences by
the quality manager and clinical director,
followed by feedback and discussion
with technical staff
25 occurrences logged since 16.6.2016
date, 23 occurrences closed, 2 open
Rectifying and
managing occurrences
• Ad hoc corrective actions
without root cause analysis or
lessons learned
▪ Staff training on how to instigate
CAPA (corrective action and preventive
action)
(IX)
Process
improvement
Quality indicators • Quality indicators not
established
▪ Identification of a selected set of
quality indicators
▪ Routine monthly data collection
(initially extraction from paper records,
later on as SQL queries)
Decrease in liquid culture
contamination rates from 13–33% to
<10% (Fig 2)
Implementing process
improvement
• No formal process ▪ Continuous process improvement
through QM team leadership
▪ Regular feedback on QI during staff
meetings and engagement of all lab staff
Decrease in liquid culture
contamination rates from 13–33% to
<10% (Fig 2)
(X)
Documents and
records
The quality manual • No quality manual ▪ Development of a quality manual
Standard operating
procedures (SOPs)
• No written SOPs ▪ Drafting of a SOP prototype
▪ Writing of SOPs in thematic blocks
(i.e. microscopy, mycobacterial culture
of primary samples)
Increase in smear positivity (Fig 1)
Document control • No system for document
control
▪ Training on document control for
NRL staff and other managerial staff in
the research organization such as
members of the workers’ council
▪ Implementation of a document
control system
Document control system established
Storing documents and
records
• Storage of paper-based patient
reports for 10 years
▪ Safe electronic storage of electronic
records with daily back-up to the central
server
(XI)
Information
management
Computerized
laboratory information
systems (LIS)
• MS Access based LIS without
functions of validation and
verification, not adhering to
national regulations
▪ Implementation of a LIS in line with
statutory regulations
▪ Entering of referral forms using optical
character recognition software and order
entry systems
New LIS implemented and fully
functioning with BSL III moving to
near paperless laboratory
Audit trails • No audit trail of data entry
available
▪ Data entry audit trail implemented as
part of the LIS system
Audit trail of data entry fully
implemented
Invoicing • Labour intensive manual
invoicing without internal checks
▪ Invoicing through LIS with internal
controls
Increase in revenue
Data protection • Institutional policy in place
• No policy within the laboratory
on whom to supply patient results
to and how
▪ Training of all staff on data protection
▪ Policy on provision of laboratory
results to clinician’s other than the
referring clinician
Improved data protection in line with
national regulations
(Continued)
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Review of facilities and safety resulted in several infrastructural changes of the existing
building including additional emergency exits, smoke detectors and fire alarms. Some infra-
structural deficiencies were addressed by optimising and standardising processes such as sam-
ple flow and delineating laboratory activities. To improve safety a waste management plan was
introduced and appropriate equipment (autoclave boxes) and consumables were purchased, a
detailed cleaning plan was developed and staff were required to wear gloves in the BSL III. The
feasibility study revealed that refurbishment of the existing building would not suffice to com-
ply with the 2013 biosafety regulations. As a result, senior management sourced and secured
financing for a new BSL III. Building permission was granted in September 2018 and comple-
tion is planned for 2020.
Documentation of equipment, purchasing and inventory was limited. Processes and docu-
mentation were agreed and an equipment and baseline stock inventory completed. Lack of
sample rejection criteria meant that all samples were processed regardless of suitability. Mini-
mal requirements for quality of samples were established, users informed and scientists and
technicians trained. Standardised operating procedures and documentation for validation and
verification of new methods were introduced. In total five new CE-marked methods (CE: Con-
formité Européenne [European conformity] with health, safety, and environmental protection
standards for products sold within the European Economic Area) have been verified up to
December 2017, and one method (DST for bedaquiline, delamanid and clofazimine) has been
validated. Up to 2017 the NRL participated in the national EQA scheme led by the NRL itself.
From 2018 the NRL took successfully part in the United States College of American Patholo-
gists (US CAP) EQA for microscopy, NAT, culture, identification and phenotypic DST.
The majority of staff had been trained at the NRL and never worked at or visited other labo-
ratories. The concept of quality management was unfamiliar to technical, scientific and admin-
istrative staff. Staff were encouraged to participate in training and visit other laboratories with
the aim to create an environment of continuous learning, promote critical thinking and moti-
vate for sustained change. A total of 25 laboratory visits by individual staff members took place
over a period of two years. External training days totalled 48 (excluding the acting laboratory
manager’s training days). In addition, diagnostic companies were invited to conduct on-the-
job trainings in small groups. A one-hour internal fortnightly teaching session was imple-
mented to introduce quality management concepts such as corrective and preventive actions,
discuss SOPs under development and inform staff about future plans and changes. The
Table 1. (Continued)
Quality system essential Review findings Actions Outcomes
(XII)
Organization
Organization
management and
structure
• Autocratic leadership within a
hierarchical structure
• No clear lines of reporting
• Roles and responsibilities not
established
▪ Appointment of a new clinical director
▪ Promotion of one of the technicians to
acting laboratory manager
▪ Organogram with clear lines of
reporting
▪ Establishment of delineated roles and
responsibilities with clear job
descriptions and competency
requirements
Sufficient, competent staff with
appropriate authority and managerial
oversight
Abbreviations: BSC–biosafety cabinet; BSL III–Biosafety laboratory III; CAP–College of American Pathologists; CAPA–corrective action and preventive action; DNA–
Desoxyribonuleic acid; DST–drug susceptibility testing; ECDC—European Center for Disease Prevention and Control; EQA–external quality assessment; LIS–
laboratory information system; NAT–Nucleic acid Amplification Test; NTM–non-tuberculous mycobacteria; NRL–National Reference Laboratory; PCR–Polymerase
Chain Reaction; QI–quality improvement; QM–quality management; SOP–standard operating procedure; SQL–structured query language; TB–tuberculosis; WHO–
World Health Organisation
https://doi.org/10.1371/journal.pone.0222925.t001
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implementation of the LIS was accompanied by intensive theoretical and practical training
(three group sessions, and three individual training sessions for each staff member).
Components of the QMS were developed using a bottom-up approach wherever possible.
Quality indicators were not established and given the largely paper-based documentation of
laboratory results were difficult to collect and analyse in real time. Initially a limited set of qual-
ity indicators (culture contamination rates, positive microscopy and NAT rates, discordances
in microscopy, NAT and culture results) was identified to introduce the concept of quality
indicator monitoring and continuous process improvement. Once the LIS was implemented
in October 2017 trends of quality indicators were analysed on a monthly basis.
SOPs for analytical processes did not exist. Staff were using product inserts to perform diag-
nostics procedures. Because none of the technicians had ever drafted a SOP, the quality man-
ager, clinical laboratory director and quality management technician did the actual writing of
SOPs and validated the content with other staff members. The development of SOPs followed
an iterative process: observation of the analytic process by the quality management team, draft-
ing of the SOP, actively seeking feedback from the technicians, amendments and edits, multi-
ple feedback rounds followed by the approval of the final SOP. Alongside the introduction of
standardised processes and improved documentation a document control system was set up.
All laboratory staff and the members of the workers council (mandatory elected body compris-
ing elected employees with mandate to protect working conditions, health and safety and
workers’ rights) were trained on document control. Laboratory documents were made avail-
able to the workers’ council on request to check compliance with working directives. Thus
members of the workers’ council had to understand and adhere to document control
procedures.
In mid 2015, an in-house access based (Microsoft 2013) LIS was introduced replacing a
completely paper-based system, where results were entered on hard-copy sample sheets (one
sheet per sample) and reports typed and signed. The access based LIS had several shortcomings
and did not comply with national regulations. Features such as technical verification, medical
authorization, audit trails, direct import of laboratory results from analysers, automated regis-
tration of samples via an optical character recognition (OCR) scanner and automated invoic-
ing were not available. Technicians continued to use paper-based sample worksheets
duplicating reporting. A new LIS (MLab, Dorner, Muehlhausen, Germany), OCR scanners for
sample registration and automated result import from analysers was introduced in October
2017. Despite limited computer literacy of technical staff, the BSL III was able to move to near
paperless result reporting. Registration of samples became less time consuming and error
prone. Automated and standardised invoicing resulted in an increase in revenue and reduction
of administrative staff time freeing 0.3 full time equivalents of administrator time.
Smear microscopy
In 2015, smears were stained using a staining automate according to the manufactore´s
instruction (Kreienbaum, Germany) and the Kinyoun staining method.[17] Briefly, the
Kinyoun method refers to an acid-fast stain used to detect any species of the genus Mycobacte-
rium. It involves the application of a primary stain (Carbol-Fuchsin), a decolorizer (acid-alco-
hol), and a counterstain (Armand Solution). In contrast to the classical Ziehl–Neelsen
staining, the Kinyoun method does not require a heating step.
A review of the existing method revealed poor quality of smears and staining which
included a high proportion of staining artefacts. As a result of the review it was decided to i)
introduce fluorescence microscopy recommended by WHO [18] with a higher sensitivity [19]
accompanied by changes such as the use of frosted slides and water filters to avoid
Quality management in diagnostics
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contamination with environmental mycobacteria from tap water ii) remove the staining auto-
mate iii) develop SOPs iv) introduce and document batch controls of staining solution as well
as positive and negative controls v) train technicians in smear preparation, staining and read-
ing vi) assess competencies vii) routinely double-check any positive slide and viii) perform
duplicate reading of ten randomly selected negative slides per week. These changes and the
completion of all documents related to quality management of smear microscopy were imple-
mented over a period of 3 months.
Before implementation of quality managed fluorescence microscopy the proportion of
respiratory samples classified as smear positive was 3.3% (Fig 1). During the implementation
and post-implementation period the proportion of respiratory samples testing smear positive
increased to 6.2% and 6.6% respectively (p-value <0.01). The odds ratio for a sample to be
tested as microscopically positive increased by 1.94 (95% CI 1.16–3.26, p = 0.012) and 2.08
(95%CI 1.41–3.06, p<0.001) comparing the time before the interventions with the scale-up
phase and the time when quality managed fluorescence microscopy was fully implemented.
The proportion of false positives was 0.02%, 0.01%, 0.02% before, during and post-implemen-
tation of the interventions respectively.
Culture contamination rates
Baseline reviews showed that contamination rates in previous years (2013–2015) exceeded the tar-
get of<10% in liquid media set by the national German microbiology standards (Fig 2).[16] This
resulted in the implementation of several measures aimed at improving quality. First the results of
the retrospective assessment were presented and discussed at one of the forth-nightly laboratory
meetings. Contamination rates were selected as one of the first quality indicators to be monitored
and data were extracted manually from paper records from April 2016 onwards. However,
because the process was not automated contamination rates were not available in real-time.
In August 2016, a study comparing different decontamination methods (three commer-
cially available methods and the in-house method) was conducted over a period of 10 weeks.
[20] For each method short SOPs were developed, technicians were trained and following
competency assessments they were observed performing the decontamination procedures.
This led to a temporary reduction of contamination rates among routinely processed samples
during the study period (Fig 2). Finally, in March 2017 the decision was taken to implement a
CE-marked commercially available method based on N-Acetyl-L-Cysteine-Sodium Hydroxide
(NALC-NAOH, MycoDDRTM, IMMY, Norman, USA). Following the implementation of a
new LIS in August-September 2017, quality indicators and statistics were generated automati-
cally by Structured Query Language (SQL) queries. Weekly meetings were held to review con-
tamination rates with all staff members involved in processing primary samples. Together with
the technicians performing the decontamination procedures prompts and aids were developed
to ensure correct incubation times and sufficient vortexing. Graphs plotting contamination
rates over time were displayed in the staff room. Over a period of two weeks, decontamination
procedures were directly observed on five separate days by the acting laboratory manager.
Contamination rates decreased from 23.6–27.6% in April-July 2016 to 10.7–17.4% in the same
period in 2017 and fell under the 10% mark in November 2017-March 2018.
DNA contamination
In 2015, the Xpert MTB/Rif (Cepheid, USA) was the main molecular diagnostic used for detec-
tion of resistance referring mutations at the NRL. In contrast, the number of samples investi-
gated using the Genotype MTBDRplus was limited, because DNA contamination was a
frequently observed event. Strict separation of pre-PCR, PCR and post-PCR processes was
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difficult due to suboptimal building design and sample flow. Further challenges included non-
directional airflow, inadequate staff training on how to prevent DNA contamination and a cul-
ture of austerity aimed at saving consumables and time. Over a period of several months, addi-
tional bench and storage space was built to allow separation of pre-PCR, PCR and post-PCR
processes. In addition, room access with regards to whom (staff) and when (time of the day)
and cleaning procedures were discussed with scientific and technical staff and agreed upon.
Any PCR run with a “positive” negative control was brought to the attention of senior manage-
ment and the run was repeated. If still positive on the repeat run, intensive cleaning was con-
ducted, new reagents and pipettes were sourced.
Fig 1. Proportion of positive microscopy slides (black line) pre- implementation of quality control measures, during implementation and post-
implementation (limited to the first respiratory sample of each patient). Culture positivity for samples included in smear analysis are shown (blue
line). Samples were comparable across different time periods. (DOI10.6084/m9.figshare.9882935) Pre-implementation: smears were stained using a staining
automate and the Kinyoun staining method. Implementation: Fluorescence microscopy was introduced accompanied by using frosted slides and water
filters. SOPs were developed including e.g. documentation of batch controls of staining solution, training of technicians and introduction of positive and
negative smear controls. Post-implementation: Quality control measures were continued and technicians were re-trained at 6 monthly intervals.
https://doi.org/10.1371/journal.pone.0222925.g001
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Between 2013 and 2017 a total of 610 individual Genotype MDRplus diagnostic runs were
performed investigating a total of 1780 samples. The median number of samples tested per run
increased from one in 2013 and 2014 to two, three and five in 2015, 2016 and 2017 respectively
(Table 2), while the proportion of negative controls showing evidence of DNA contamination
Fig 2. Contamination rates in liquid culture over time. Baseline reviews showed that contamination rates between the years 2013–2015 exceeded the targets
of<10% in liquid media (3 representative months/year are shown). Between 2016 and 2017, different approaches (A–decontamination study; B–CE-marked
decontamination kit accompanied by standard operating procedures and staff training, C–regular real time review of contamination rates with staff, direct
observation of analytic process) were applied and impact on contamination rates were measured.
https://doi.org/10.1371/journal.pone.0222925.g002
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decreased from 38.2% in 2013 to 8.1% in 2017 (p value <0.01). The odds ratio for a run with
evidence of DNA contamination was 0.91 (95%CI 0.53–1.57) for 2014 compared to 2013, but
decreased for the subsequent years to 0.42 (95%CI 0.23–0.75), 0.28 (95%CI 0.15–0.54) and
0.14 (95%CI 0.07–0.29).
Of the 11 runs with “positive” negative controls in 2017 seven occurred in July and August
(Fig 3). These triggered corrective and preventive actions including repeat testing of the
Table 2. Summary of Genotype MDRplus tests performed between 2013 and 2017.
Year Total number
of runs
Median (IQR) number of
diagnostic samples per run
Mean number of
diagnostic samples per
run
Proportion (95%CI) of negative
controls showing evidence of
contamination
Odds ratio (95%CI) for a negative
control showing evidence of
contamination
2013 116 1 (1; 1) 1.33 38.2% (29.1; 47.9) 1
2014 112 1 (1; 2) 1.61 36.0% (27.1; 45.7) 0.91 (0.53; 1.57)
2015 127 2 (1; 3) 2.15 20.6% (13.9; 28.8) 0.42 (0.23; 0.75)
2016 115 3 (2; 5) 3.33 14.9% (8.9; 22.8) 0.28 (0.15; 0.54)
2017 140 5 (3; 7.5) 5.64 8.1% (4.1; 14.0) 0.14 (0.07; 0.29)
CI: confidence interval; IQR interquartile range.
https://doi.org/10.1371/journal.pone.0222925.t002
Fig 3. Proportion of PCR runs with evidence of DNA contamination over 5 years. Between 2013 and 2017 a total of 610 PCR runs were performed. The
proportion of negative controls showing evidence of DNA contamination decreased from 38.2% in 2013 to 8.1% in 2017 by separating pre-PCR and post-
PCR processes followed by staff training. (DOI 10.6084/m9.figshare.9882935).
https://doi.org/10.1371/journal.pone.0222925.g003
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clinical specimens, replacement of pipettes and mastermix and intensive cleaning. These mea-
sures decreased DNA contamination immediately (4.1%; 95%CI 0.49–13.98). Excluding the
months of July and August DNA contamination was evident in 3.6% (95%CI 0.98–8.89) runs
in 2017.
Discussion
This study demonstrates the impact of quality management in a National TB reference labora-
tory in a high-income country across different methods: smear microscopy, culture and
molecular diagnostics. Implementation of quality managed fluorescence microscopy doubled
the yield in respiratory samples, while contamination rates in liquid media decreased signifi-
cantly from over 20% at the beginning of this study to less than 10% during the most recent
follow-up. Retrospective data collection showed evidence of DNA contamination in more
than a third of PCR runs in 2013 and 2014. The odds of DNA contamination decreased by
85% comparing 2013 data with 2017 data.
While QMS implementation has not been completed and the laboratory is not yet accred-
ited, the results show significant improvements due to introduction of quality management
processes. In parallel with the implementation of a QMS and LIS finances have been secured
to build a new BSL III. The decision has been taken to defer accreditation until the new labora-
tory has been completed. This is currently planned for 2020. Publication of our experience and
these findings at this time prior to reaching accreditation serves two purposes. First our data-
driven approach by implementing measurement of the impact of QMS using trend analysis of
quality indicators has already demonstrated substantial benefit. The analysis has been a key
enabler to motivate for the additional investment needed. Secondly, although accreditation is
our eventual aim, laboratories considering improvement of QMS can follow our approach
with or without accreditation as the final goal.
Success in attaining sustained improvement cannot be attributed to a single measure. A
combination of committed senior leadership, significant financial resources and a bottom-up
approach was crucial for these achievements. In addition, a non-blame culture of continuous
improvement has resulted in enhanced staff competency and fostered their ability of critical
appraisal, improved operational consistency and reliability and teamwork. The baseline review
included interviews with all staff members and revealed that most of them were afraid to make
any mistakes and even more of being caught. A two-day team building exercise in February
2016 showed that lack of skill and understanding of analytic procedures impeded effective
teamwork and communication. Therefore, a special emphasis was placed on training, exposure
to other laboratories and communication through in-house seminars and daily staff meetings.
Unfortunately, no formal staff feedback was sought. However, a study conducted in three
laboratories in the United Kingdom reporting that the majority of laboratory technicians
thought the documentation required for accreditation increased the workload without
improving quality of test results.[21] In contrast, laboratory managers and clinicians in the
United Kingdom and South Korea felt that accreditation resulted in better laboratory perfor-
mance with more documentation, better health and safety and training procedures and
improved infrastructure.[22, 23]
There seems widespread agreement that laboratory quality management is important for
patient safety and impacts on quality of clinical care.[4, 11] However, studies reporting on the
impact of full-scale implementation of QMS and/or accreditation on laboratory performance
are relatively few.[9, 10, 24–26] We have recently conducted a systematic review showing that
quality improvement measures had indeed a measurable impact in TB laboratories in low- and
lower-middle income countries.[27] Only one of the studies included in the review reported
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on the effect of implementing a comprehensive QMS followed by accreditation.[9] All other
studies described the effect of various activities aimed at improving quality such as EQAs,
supervisory visits and staff training.
One of the main issues of measuring the effect of QMS is the measurement of quality before
implementing QMS. Data collection on quality indicators requires partial QMS implementa-
tion. This in turn makes it difficult to assess the full impact of QMS on quality indicators.
In this study, pre-intervention data were collected retrospectively. Hence data collection of
quality indicators itself could not have impacted on performance. Outcomes in this study were
analyzed using an uncontrolled before-and-after comparison, which is always vulnerable to
coincidental time trends. However, impact was measured across three different analytic tests
over a prolonged time period. Thus changes due to seasonal variations or differences in patient
population are unlikely to explain the significant differences detected over time.
Unfortunately, we did not collect any data on cost and hence were unable to calculate cost-
effectiveness or report on any cost-savings.
Over the past decade the need to improve laboratory quality in low and middle-income
countries has been widely acknowledged.[28–30] The Strengthening Laboratory Management
Toward Accreditation (SLMTA) initiative launched in 2009 has had a substantive impact on
provision of quality laboratory services and patient care.[31–34] However, this study shows
that quality management is effective regardless of low or high resource settings. It serves as a
stark reminder that while quality management is worth our while it is cost and resource inten-
sive and requires full commitment from senior management.
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